Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Marsh KÖNIGS |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled Trial / Dorinde M. VAN ANDEL in Journal of Autism and Developmental Disorders, 54-3 (March 2024)
[article]
Titre : Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled Trial Type de document : Texte imprimé et/ou numérique Auteurs : Dorinde M. VAN ANDEL, Auteur ; Jan J. SPRENGERS, Auteur ; Marsh KÖNIGS, Auteur ; Maretha V. DE JONGE, Auteur ; Hilgo BRUINING, Auteur Article en page(s) : p.894-904 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : We present the secondary-analysis of neurocognitive tests in the 'Bumetanide in Autism Medication and Biomarker' (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (??1 mg twice-daily) in unmedicated children 7-15 years with ASD. Children with IQ???70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to ??0.013,p = .034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to ??0.001,p = .042). This study offers perspectives to include neurocognitive tests in ASD trials. En ligne : https://doi.org/10.1007/s10803-022-05841-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=524
in Journal of Autism and Developmental Disorders > 54-3 (March 2024) . - p.894-904[article] Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled Trial [Texte imprimé et/ou numérique] / Dorinde M. VAN ANDEL, Auteur ; Jan J. SPRENGERS, Auteur ; Marsh KÖNIGS, Auteur ; Maretha V. DE JONGE, Auteur ; Hilgo BRUINING, Auteur . - p.894-904.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 54-3 (March 2024) . - p.894-904
Index. décimale : PER Périodiques Résumé : We present the secondary-analysis of neurocognitive tests in the 'Bumetanide in Autism Medication and Biomarker' (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (??1 mg twice-daily) in unmedicated children 7-15 years with ASD. Children with IQ???70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to ??0.013,p = .034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to ??0.001,p = .042). This study offers perspectives to include neurocognitive tests in ASD trials. En ligne : https://doi.org/10.1007/s10803-022-05841-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=524